|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Sheba Medical Center |
|---|---|
| Information provided by: | Sheba Medical Center |
| ClinicalTrials.gov Identifier: | NCT00855270 |
Purpose
This study is designed to test the hypothesis that a single Hydrocortisone intra venous injection within 6 hours post-trauma facilitates physiological recovery thereby preventing the development of Post Traumatic Stress Disorder (PTSD) in the months following the event. In the absence of such treatment (i.e., under placebo conditions), we hypothesize that a greater proportion of persons would develop PTSD (i.e., fail to recover from acute effects).
| Condition | Intervention |
|---|---|
|
Post Traumatic Stress Disorder |
Other: Saline Drug: Hydrocortisone |
| Study Type: | Interventional |
| Study Design: | Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study |
| Official Title: | The Efficacy of a Single Dose IV Hydrocortisone Given Within 6 Hours of Exposure to a Traumatic Event in PTSD Prevention |
| Estimated Enrollment: | 24 |
| Study Start Date: | April 2009 |
| Estimated Study Completion Date: | August 2010 |
| Estimated Primary Completion Date: | August 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
saline: Placebo Comparator
An IV injection of saline will be administered to the control group in a double blind, randomized manner.
|
Other: Saline
IV saline will be used as placebo for control
|
|
Hydrocortisone: Experimental
IV hydrocortisone will be given in a double blind random manner as the active treatment group
|
Drug: Hydrocortisone
A single dose 18-28 mg of Intra Venous Hydrocortisone.18 mg will be administrated to participants weighing 45-59 kg. 20 mg will be administrated to participants weighing 60-69 mg.25 mg will be administrated to participants weighing 70-89 kg. 28 mg will be administrated to participants weighing 90-99 kg
|
This is a double-blind, placebo-controlled trial in which trauma victims are randomized to receive a single intravenous injection of either Hydrocortisone (18-28mg)or placebo within the first six hours following trauma exposure. To provide a pre-treatment baseline, participants will receive a medical and psychological evaluation prior to treatment. After two weeks the research assistant or study psychiatrist will perform behavioral ratings and complete history details pertaining to PTSD risk factors. Participants will be assessed again by the study psychiatrist or research assistants at 1 and 4 months. Eligible subjects will include men and women over the age of 18, who have been exposed to an event meeting the DSM-IV "A.1" criterion for trauma exposure, and who provide written, informed consent to participate in the study. In order to recruit persons who are more likely to be at risk for the development of PTSD, we will only randomize persons expressing marked anxiety, emotional distress or dissociation, as assessed by the Visual Analog Scales. Potential participants will be recruited from trauma victims arriving at the Chaim Sheba Medical Center Emergency Room.
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Joseph Zohar, M.D | 972-3-5303300 | joseph.zohar@sheba.health.gov.il |
| Contact: Hila Yahalom, M.D | 972-54-4233170 | hilahorn@netvision.net.il |
| Israel | |
| Sheba Medical Center | Recruiting |
| Ramat-Gan, Israel | |
| Contact: Joseph Zohar, M.D. 972-3-5303300 joseph.zohar@sheba.health.gov.il | |
| Contact: Hila Yahalom, M.D. 972-54-4233170 hilahorn@netvision.net.il | |
| Principal Investigator: Joseph Zohar, M.D | |
| Principal Investigator: | Joseph Zohar, M.D | Sheba Medical Center |
More Information
| Responsible Party: | Sheba Medical Center ( Prof. Joseph Zohar ) |
| Study ID Numbers: | SHEBA-09-6884-JZ-CTIL |
| Study First Received: | March 3, 2009 |
| Last Updated: | January 31, 2010 |
| ClinicalTrials.gov Identifier: | NCT00855270 History of Changes |
| Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
|
PTSD |
|
Anti-Inflammatory Agents Disease Hydrocortisone Cortisol succinate Stress Stress Disorders, Traumatic Pharmacologic Actions |
Pathologic Processes Anxiety Disorders Mental Disorders Therapeutic Uses Stress Disorders, Post-Traumatic Hydrocortisone acetate |